FREE PAPER HCV TREATMENT O‐24: The German multicenter cohort on direct antiviral agents in HCV‐ and HIV/HCV‐infected patients (GECODAA)

minorities received transarterial embolisation (3.5%), transarterial chemoperfusion (3.1%) or TACE with drug-eluting beads (1.6%) as first transarterial treatment. Three hundred and eighty-seven patients (79.3%) received TACE as first HCC-specific therapy. 52.7% received TACE only once, followed by 18.4% with two and 10.5% with three TACE treatments. The remaining patients received more than three TACEs with a maximum of 17 TACES in one patient. Interval between first and second TACE was mean 140 257 (33–2376) days. 57.4% of the patients were diagnosed with more than three HCC nodules. 19.7%, 11.3% and 9% of the patients were diagnosed with one, two and three nodules, respectively. The mean diameter of the largest lesions was 59 36 mm (ranging 4–226). 28.9% of the patients presented with a lesion larger than 70 mm. In 64.5% of all patients, tumour control by means of disease stabilisation or response after first TACE was achieved. 16.6% reached a response. Median overall survival (mOS) was 27 months in the total population. Cox proportional hazards regression analysis revealed size of the largest lesion ≥70 mm and AST increase ≥25% of baseline after first TACE as factors significantly associated with death (p = 0.047; p = 0.002). Patients that fullfilled the Milan criteria prior the first TACE reached an mOS of 52 months, which was significantly better than in patients beyond the Milan criteria (p = 0.000; log rank, Hazard ratio 0.2). Patients with extrahepatic spread and/ or vascular invasion were identified with a poor mOS of 15 months. CONCLUSION: Patients treated with TACE have a very good outcome. In particular, patients with HCC lesions <70 mm, without extrahepatic spread and vascular invasion and AST increase <25% of baseline after first TACE presented with a most beneficial survival.